Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451189 | 1.00 | KCNH2 (0.35) | KCNH2PRMT5HCRTR1HCRTR2PRCP | |
| SCHEMBL14655207 | 1.00 | KCNH2 (0.35) | KCNH2PRMT5HCRTR1HCRTR2PRCP | |
| SCHEMBL14841827 | 0.85 | PARP1 (0.37) | KCNH2HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL12333084 | 0.85 | PARP1 (0.37) | KCNH2HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL2386860 | 0.85 | PARP1 (0.37) | KCNH2HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL14655351 | 0.83 | CYP2C9 (0.46) | KCNH2PRCPCYP2C9 | |
| SCHEMBL14655274 | 0.83 | CYP2C9 (0.46) | KCNH2PRCPCYP2C9 | |
| SCHEMBL14841664 | 0.83 | CYP2C9 (0.46) | KCNH2PRCPCYP2C9 | |
| SCHEMBL14841275 | 0.83 | KMT2A (0.38) | KCNH2HCRTR1HCRTR2CYP2C9HTR2B | |
| SCHEMBL14655245 | 0.83 | KMT2A (0.38) | KCNH2HCRTR1HCRTR2CYP2C9HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2550267-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119853-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BLVRB, RRP1B, C1QBP | KCNH2 2848/4885PRMT5 1153/4885HCRTR1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.